Три преимущества торемифена, или Тренд современной гормонотерапии

Е. И. Борисова; С. Л. Гуторов

doi:10.21518/2079-701X-2015-8-60-65

Три преимущества торемифена, или Тренд современной гормонотерапии

Е. И. Борисова, С. Л. Гуторов

https://doi.org/10.21518/2079-701X-2015-8-60-65

Полный текст:

PDF (Rus)

Аннотация

Внедрение торемифена в клиническую практику существенно расширяет возможности современной эндокринотерапии люминальных субтипов рака молочной железы. Торемифен демонстрирует как минимум равную эффективность с тамоксифеном, но при этом имеет более благоприятный спектр побочных эффектов, включая тромбоэмболические осложнения. Данные преимущества позволяют значительно снизить частоту нерационального прекращения терапии. Перспективной представляется также возможность безопасного применения высоких доз торемифена, включая изучаемые режимы предоперационной терапии.

Ключевые слова

рак молочной железы, селективные модуляторы рецепторов эстрогена, торемифен, breast cancer, selective estrogen receptor modulators, toremifene

Об авторах

Е. И. Борисова

Российский онкологический научный центр им. Н.Н. Блохина, Москва
Россия

С. Л. Гуторов

Российский онкологический научный центр им. Н.Н. Блохина, Москва
Россия

Список литературы

1. Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. Journal of steroid Biochemistry and Molecular Biology. 142 (2014) 142-154; Mirkin S, Pickar JH. Selective estrogen receptor modulator (SERMs): A review of clinical data. Maturitas 80 (2015) 52-57.

2. Di SaLLe E, Zaccheo T, Ornati G. Antiestrogenic and antitumor properties of the new tripheny-LethyLene compound, Fc-1157a. J. Steroid Biochem. Mol. Biol., 1990, 36: 203-206.

3. Goetz MP, Suman VJ, Hoskin TL et aL. CYP2D6 MetaboLism and Patient Outcome in the Austrian Breast and CoLorectaL Cancer Study Group TriaL (ABCSG) 8. Clin Cancer Res, 2013, 19: 500-7,

4. Borges S, Desta Z, Jin Y et aL. Composite functionaL genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol, 2010, 50: 450-8.

5. Pyrhonen S, VaLavaara R, Modig H et aL. Comparison of toremifene and tamoxifen in post-menopausaL patients with advanced breast cancer: a randomized doubLe-bLind, the nordic phase III study. Br J Cancer, 1997, 76: 270-7,

6. Pyrhonen S, ELLmen J, Vuorinen J et aL. Metaanalysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat, 1999? 56(2): 133-43.

7. Mao C, Yang ZY, He BF et aL. Toremifene versus tamoxifen for advanced breast cancer. Cochrane Database Syst Rev, 2012, 7: CD008926.

8. Gershanovich M, Garin A, BaLtina D et aL. A phase III comparison of two toremifene doses to tamoxifen in postmenopausaL women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat, 1997, 45: 251-62.

9. Nomura Y, Tominaga T, Abe O et aL. CLinicaL evaLuation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer - a comparative study by a doubLe bLind method with tamoxifen. Gan To Kagaku Ryoho, 1993, 20: 247-258.

10. ZejnaLov RS, Musaev IN, GiyasbejLi SR et aL. Comparative anaLysis of the efficacy of toremi-feine, tamoxifen and LetrozoLe in treatment of patients with disseminated breast cancer. Onkologiya, 2006, 8: 1-4.

11. Sawaki M, Wada M, Sato Y et aL: High-dose toremifene as first-Line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: a muLticenter phase II study. Oncol Lett, 2012, 3: 61-65.

12. Yamamoto Y, Ishikawa T, Hozumi Y et aL. Randomized controLLed triaL of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidaL aromatase inhibitor in postmenopausaL women with hormone receptor-positive metastatic breast cancer. BMC Cancer, 2013, 13: 239.

13. VogeL CL, Shemano I, SchoenfeLder J et aL. MuLticenter phase II efficacy triaL of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol, 1993, 11: 345-50.

14. Gams RA, Hajba A. High dose toremifene (TOR) in the management of advanced breast cancer refractory to tamoxifen (TAM and other therapies). Proc Natl Acad Sci uSa, 2002, 21, abstract 215.

15. VogeL CL, Johnston MA, Capers C et aL. Toremi-fene for Breast Cancer: A Review of 20 Years of Data. Clinical Breast Cancer, 2014, 14(1), 1-9.

16. Mori R, Nagao Y. High-dose toremifene for fuL-vestrant-resistant metastatic breast cancer: a report of two cases. Case Rep Oncol, 2014, 7: 383-388.

17. HoLLi K, VaLavaara R, BLanco G et aL. Safety and efficacy resuLts of a randomized triaL comparing adjuvant toremifene and tamoxifen in postmenopausaL patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol, 2000, 18: 3487-94.

18. Pagani O, GeLber S et aL. InternationaL Breast Cancer Study Group. Toremifene and tamoxifen are equaLLy effective for earLy-stage breast cancer: first resuLts of InternationaL Breast Cancer Study Group TriaLs 12-93 and 14-93. Ann Oncol, 2004, 15: 1749.

19. Lewis JD, Chagpar AB, Shaughnessy EA et aL. ExceLLent outcomes with adjuvant toremifene or tamoxifen in earLy stage breast cancer. Cancer, 2010, 116: 2307-15.

20. HoLLi K. Finnish Breast Cancer Group. Tamoxifen versus toremifene in the adjuvant treatment of breast cancer. Eur J Cancer, 2002; 38: 37-8.

21. Zhou WB, Ding O, Chen L et aL. Toremifene is an effective and safe aLternative to tamoxifen in adjuvant endocrine therapy for breast cancer: resuLts of four randomized triaLs. Breast Cancer Res Treat, 2011, 128: 625-31.

22. Gu R, Jia W, Zeng Y et aL. A comparison of survivaL outcomes and side effects of toremifene or tamoxifen therapy in premenopausaL estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. BMC Cancer, 2012, 12: 161.

23. Oin T, Yuan ZY, Peng RJ et aL. Efficacy and toLer-abiLity of toremifene and tamoxifen therapy in premenopausaL patients with operabLe breast cancer: a retrospective anaLysis. Curr Oncol, 2013, 20: 196-204.

24. Mustonen MVJ, Pyrhonen S, KeLLokumpu-Lehtinen P-L. Toremifene in the treatment of breast cancer. World J Clin Oncol, 2014, 10; 5(3): 393-405 ISSN 2218-4333 (onLine).

25. GyLLing H, Pyrhonen S, MantyLa E et aL. Tamoxifen and toremifene Lower serum choLesteroL by inhibition of deLta 8-choLesteroL conversion to LathosteroL in women with breast cancer. J Clin Oncol, 1995, 13: 2900-2905.

Для цитирования:

Борисова Е.И., Гуторов С.Л. Три преимущества торемифена, или Тренд современной гормонотерапии. Медицинский Совет. 2015;(8):60-65. https://doi.org/10.21518/2079-701X-2015-8-60-65

For citation:

Borisova E.I., Gutorov S.L. Three benefits of toremifene, or a trend in the current hormone therapy. Medical Council. 2015;(8):60-65. (In Russ.) https://doi.org/10.21518/2079-701X-2015-8-60-65